NASDAQ:UTHR United Therapeutics (UTHR) Stock Forecast, Price & News $220.25 +1.37 (+0.63%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$217.61▼$220.8850-Day Range$205.19▼$232.9952-Week Range$201.65▼$283.09Volume311,513 shsAverage Volume494,164 shsMarket Capitalization$10.32 billionP/E Ratio14.83Dividend YieldN/APrice Target$294.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability United Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside33.8% Upside$294.67 Price TargetShort InterestHealthy2.86% of Shares Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment1.20Based on 8 Articles This WeekInsider TradingSelling Shares$42.22 M Sold Last QuarterProj. Earnings Growth9.11%From $18.33 to $20.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.20 out of 5 starsMedical Sector7th out of 981 stocksPharmaceutical Preparations Industry3rd out of 463 stocks 3.3 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 7 buy ratings, no hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $294.67, United Therapeutics has a forecasted upside of 33.8% from its current price of $220.25.Amount of Analyst CoverageUnited Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.86% of the outstanding shares of United Therapeutics have been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently decreased by 8.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 3.4 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for United Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows6 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold 6,172,200.73% more of their company's stock than they have bought. Specifically, they have bought $684.00 in company stock and sold $42,218,537.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.63% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 9.11% in the coming year, from $18.33 to $20.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 14.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.42.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 14.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.68.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About United Therapeutics (NASDAQ:UTHR) StockUnited Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.Read More Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Stock News HeadlinesMay 18, 2023 | marketbeat.comAnalysts Say These 2 Mid-Cap Biotechs Have 2x Potential (UTHR)These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.June 2, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 6,000 SharesJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 20, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on United Therapeutics (NASDAQ:UTHR)May 16, 2023 | bizjournals.comUnited Therapeutics’ Revivicor advancing Virginia manufacturing facility for pig organsMay 13, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Receives $285.82 Consensus Price Target from AnalystsMay 10, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Sells $80,338.94 in StockMay 10, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Forecasted to Earn Q2 2023 Earnings of $4.59 Per ShareJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 9, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for United Therapeutics Co. (NASDAQ:UTHR) Reduced by AnalystMay 5, 2023 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Stock Rating Upgraded by StockNews.comMay 5, 2023 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider SellingMay 4, 2023 | msn.comLadenburg Thalmann Maintains United Therapeutics (UTHR) Buy RecommendationMay 4, 2023 | seekingalpha.comUnited Therapeutics: Deep Value At 8-9% Earnings Yield, 12.4x P/EMay 4, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for United TherapeuticsMay 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for United Therapeutics (UTHR)May 4, 2023 | msn.comUnited Therapeutics (UTHR) Q1 Earnings Beat, Sales MissMay 4, 2023 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Cut to $256.00 by Analysts at LADENBURG THALM/SH SHMay 4, 2023 | americanbankingnews.comLADENBURG THALM/SH SH Trims United Therapeutics (NASDAQ:UTHR) Target Price to $256.00May 4, 2023 | americanbankingnews.comMartine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockMay 4, 2023 | finance.yahoo.comQ1 2023 United Therapeutics Corp Earnings CallMay 3, 2023 | finance.yahoo.comWhy United Therapeutics Shares Are Falling TodayMay 3, 2023 | finance.yahoo.comHere's What Key Metrics Tell Us About United Therapeutics (UTHR) Q1 EarningsMay 3, 2023 | finance.yahoo.comUnited Therapeutics Corporation Reports First Quarter 2023 Financial ResultsMay 3, 2023 | finance.yahoo.comUnited Therapeutics (UTHR) Q1 Earnings Beat EstimatesMay 3, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 8,000 SharesMay 1, 2023 | americanbankingnews.comUnited Therapeutics (UTHR) Set to Announce Quarterly Earnings on WednesdaySee More Headlines UTHR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Company Calendar Last Earnings5/03/2023Today6/06/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees965Year Founded1996Price Target and Rating Average Stock Price Forecast$294.67 High Stock Price Forecast$375.00 Low Stock Price Forecast$230.00 Forecasted Upside/Downside+33.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$14.85 Trailing P/E Ratio14.83 Forward P/E Ratio12.02 P/E GrowthN/ANet Income$727.30 million Net Margins36.76% Pretax Margin47.13% Return on Equity15.49% Return on Assets12.28% Debt Debt-to-Equity Ratio0.16 Current Ratio9.84 Quick Ratio9.52 Sales & Book Value Annual Sales$1.94 billion Price / Sales5.33 Cash Flow$17.32 per share Price / Cash Flow12.72 Book Value$105.24 per share Price / Book2.09Miscellaneous Outstanding Shares46,850,000Free Float40,991,000Market Cap$10.32 billion OptionableOptionable Beta0.60 Social Links Key ExecutivesMartine A. RothblattChairman & Chief Executive OfficerMichael Ian BenkowitzPresident & Chief Operating OfficerJames Christopher EdgemondTreasurer, Chief Financial & Accounting OfficerPaul A. MahonSecretary, Executive VP & General CounselDewey SteadmanHead-Investor RelationsKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDImmunoGenNASDAQ:IMGNView All CompetitorsInsiders & InstitutionsPaul A MahonSold 6,000 sharesTotal: $1.25 M ($209.11/share)ProShare Advisors LLCSold 1,345 shares on 5/26/2023Ownership: 0.013%Toroso Investments LLCBought 4,253 shares on 5/23/2023Ownership: 0.029%Seaport Global Advisors LLCBought 162 shares on 5/23/2023Ownership: 0.004%Ameriprise Financial Inc.Bought 7,359 shares on 5/22/2023Ownership: 0.185%View All Insider TransactionsView All Institutional Transactions UTHR Stock - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price forecast for 2023? 9 equities research analysts have issued twelve-month price targets for United Therapeutics' stock. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they predict the company's share price to reach $294.67 in the next twelve months. This suggests a possible upside of 35.1% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2023? United Therapeutics' stock was trading at $278.09 at the start of the year. Since then, UTHR stock has decreased by 21.6% and is now trading at $218.15. View the best growth stocks for 2023 here. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings data on Wednesday, May, 3rd. The biotechnology company reported $4.86 earnings per share for the quarter, beating analysts' consensus estimates of $4.26 by $0.60. The biotechnology company earned $506.90 million during the quarter, compared to analyst estimates of $514.37 million. United Therapeutics had a net margin of 36.76% and a trailing twelve-month return on equity of 15.49%. The business's revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.03 EPS. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Formidable Fortress ETF (KONG), The Acquirers Fund (ZIG), Invesco Dynamic Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Subversive Mental Health ETF (SANE), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ) and Inspire Faithward Mid Cap Momentum ETF (GLRY). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). What is United Therapeutics' stock symbol? United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR." Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.14%), Wellington Management Group LLP (8.07%), Avoro Capital Advisors LLC (6.13%), FMR LLC (5.42%), Renaissance Technologies LLC (4.75%) and State Street Corp (3.83%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is United Therapeutics' stock price today? One share of UTHR stock can currently be purchased for approximately $218.15. How much money does United Therapeutics make? United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.22 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $14.85 on an earnings per share basis. How many employees does United Therapeutics have? The company employs 965 workers across the globe. How can I contact United Therapeutics? United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291. This page (NASDAQ:UTHR) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.